首页> 外文期刊>Open Journal of Obstetrics and Gynecology >Single Nucleotide Polymorphism-Based Chromosomal Microarray Evaluation of Hydatidiform Moles: A US National Reference Laboratory Experience
【24h】

Single Nucleotide Polymorphism-Based Chromosomal Microarray Evaluation of Hydatidiform Moles: A US National Reference Laboratory Experience

机译:基于单核苷酸多态性的染色体微阵列评价瓦湿液体:美国国家参考实验室经验

获取原文
           

摘要

Objectives : This retrospective study evaluated 1) benefits of single nucleotide polymorphism (SNP)-based chromosomal microarrays (CMAs) in the diagnosis of complete hydatidiform mole (CHM) and partial HM (PHM) in products of conception (POC) and amniotic fluid (AF) specimens, and 2) frequency of whole-genome uniparental disomy (wgUPD) and triploidy in POC and AF specimens received at a US national reference laboratory. Methods: We reviewed consecutive 2138 POC and 3230 AF specimens and identified the cases with wgUPD and triploidy which are associated with molar pregnancy. Results: Of 2138 consecutive POC specimens tested, SNP-based CMA detected wgUPD in 10 (0.47%) and triploidy in 84 (3.93%). Of the 10 wgUPD cases, 9 (90%) were confirmed as CHM. Of 3230 consecutive AF specimens, the array detected wgUPD in 1 case (0.03%) and triploidy in 11 (0.34%). Conclusions: SNP-based microarray allows detection of wgUPD in POC and AF specimens at a US national reference laboratory. Correctly diagnosing HM and differentiating CHM from PHM are important for clinical management. The effective SNP-based CMA detection of wgUPD in CHM may enable physicians to monitor patients at risk for gestational trophoblastic disease and neoplasm. Conventional chromosome analysis of POC has a high failure rate, cannot be performed on formalin-fixed paraffin embedded samples, and cannot detect wgUPD. Further multi-institutional collaborative assessmen on accuracy, cost-effectiveness, and adequate access to SNP-based CMA, may lead this testing platform to be considered as the first-tier analysis tool for POC specimens, including those showing PHM or CHM.
机译:目的:这种回顾性研究评估了1)种核苷酸多态性(SNP)的染色体微阵列(CMA)在概念(POC)和羊水的产品中的完全瓦尔(CHM)和部分HM(PHM)中的染色体微阵列(CMA)的益处( AF)标本和2)在美国国家参考实验室的PoC和AF标本中的全基因组发给人强生(WGUPD)和三倍体的频率。 方法:我们审查了连续2138个PoC和3230 AF标本,并鉴定了WGUPD和三倍体与摩尔妊娠相关的病例。 结果:2138个连续的POC标本测试,基于SNP的CMA检测到10(0.47%)和三倍体中的WGUPD在84(3.93%)。在10例WGUPD病例中,9(90%)确认为CHM。在3230个连续的AF标本中,阵列在11例(0.03%)和三倍体中检测到WGUPD(0.03%),11(0.34%)。 结论:基于SNP的微阵列允许在美国国家参考实验室检测POC和AF标本的WGUPD。正确诊断HM和区分PHM的CHM对于临床管理很重要。 CHM中WGUPD的有效SNP的CMA检测可能使医生能够监测患有妊娠期滋养细胞和肿瘤的风险的患者。 POC的常规染色体分析具有高的损失率,不能对福尔马林固定的石蜡包埋的样品进行,并且无法检测WGUPD。关于精度,成本效益和充分访问对基于SNP的CMA的进一步多机构协作评估,可能导致该测试平台被视为PoC标本的第一层分析工具,包括显示PHM或CHM的分析工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号